Table 3. Baseline characteristics of patients used for Training and Comorbidities studies.
| Training(final fitting) | Comorbidities(InFoRM 512) | |
| Number of samples | (n = 249) | (n = 512) |
| % Female | 75 | 76 |
| % RF+ | 61a | 77b |
| % anti-CCP+ | 58c | 65d |
| Median age (IQR) | 58 (49–67) | 59 (50–68) |
| Median DAS28-CRP (IQR) | 3.8 (1.6–6.4) | 3.3 (2.3–4.7) |
| Median TJC (IQR) | 5 (0–18) | 2 (0–8) |
| Median SJC (IQR) | 4 (0–17) | 2 (0–6) |
| Median CRP, mg/L (IQR) | 3.8 (1.3- 20.5) | 4.3 (1.9–12) |
| Mean PG (IQR) | 3.9 (1–7) | 3.5 (1–5.5) |
| Mean MBDA (IQR) | 42 (33–50) | 40 (30–59) |
RF and anti-CCP status was not available for all patients, evaluable patients noted:
a
n = 198;
b
n = 505;
c
n = 232;
d
n = 511.
IQR, inter-quartile range.